MEDS
DataMeds AI Inc. · NASDAQ
- Market cap
- $3.1M
DataMeds AI Inc. (MEDS) is an Other Pharmaceuticals company listed on NASDAQ. In the last 30 days Quantisnow tracked 9 wire items for MEDS, including 8 market updates and 1 press release or news item. The most recent was published Nov 16, 2026.
Financial highlights
Full financials- Revenue, TTM
- $7.68M
- Revenue growth
- -77.5%
- Net income, TTM
- -$43.37M
- Net margin
- -564.8%
- Cash
- $476.6K
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks39-62%
2026-05-242026-11-15
Mix2690d
- Market22(85%)
- Other3(12%)
- Offering1(4%)
Activity · 52 weeks3933 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- NEWSDataMEDS AI Releases CEO LetterInterim Co-CEO Lays Out Strategy Across Recent Investments Focused on the Synergies to in the Company's Emerging Healthcare EcosystemOngoing turnaround focused on financial discipline, strategic investments and proof-of-concept revenue generation prior to driving for scale in 2027Unique roadmap to consolidate future of U.S. healthcare intellectual property provides once-in-a-generation opportunity for consumers to fight backA recent Menlo Ventures report notes that healthcare is AI's biggest vertical market with spend growing 2.5x to $3.7B, more than double the next largest vertical (legal) TAMPA, FL / ACCESS Newswire / November 16, 2026 / DataMeds AI, Inc. ("DataMeds SI," "DataMEDS" o
- NEWSDataMEDS AI Reports 50% Sequential Revenue Growth in Third Quarter 2026 From Second Quarter 2026, Delivers Net Profit Per Share of $2.72 and Provides Business UpdateThird quarter 2026 revenue of $2.7 million, up 50% from $1.8 million in the second quarter of 2026, primarily driven by growth in Corexa Pharmacy drug dispensingLaunch of the Health Lives Here mobile app, partnered with the NFL Alumni Health marketing platform, gives Corexa Pharmacy a unique customer acquisition channel to dispense FDA-approved GLP-1 medications and the medical food Forzet™ for the dietary management of muscle loss associated with weight loss therapiesExclusive license to the REBOOT GLP-1 patient management platform and intellectual property creates moat to scale customer acquisition and increase long-term customer value through patented, AI-assisted patient management servi
- NEWSDataMEDS AI Signs MOU to Deploy Health Lives Here GLP-1 Patient Management Program with Florida-Based HMONFL Alumni Health to support HMO member engagementRelationship centers on improving member GLP-1 related outcomes through use of the Health Lives Here app and easy access to telehealth, pharmacy and lab testing servicesAim is to reduce hospitalizations and adverse drug events for patients on GLP-1 therapy TAMPA, FL / ACCESS Newswire / November 5, 2026 / DataMeds AI, Inc. ("DataMeds SI," "DataMEDS" or the "Company") (NASDAQ:MEDS), a healthcare company that integrates its health information technology and physical infrastructure with its EinsteinRx™ artificial intelligence platform and PharmacyChain™ blockchain-enabled smart contracts platform, today announced that it has signed a Memora
- NEWSDataMEDS AI Announces Termination of Second Amended and Restated Letter of IntentTAMPA, FL / ACCESS Newswire / November 3, 2026 / DataMeds AI, Inc. ("DataMeds SI," "DataMEDS" or the "Company") (NASDAQ:MEDS), a healthcare company that integrates its health information technology and physical infrastructure with its EinsteinRx™ artificial intelligence platform and PharmacyChain™ blockchain-enabled smart contracts platform, today announced that it has terminated the Second Amended and Restated letter of intent dated October 19, 2026 ("2nd LOI") with Datavault AI Inc. ("Datavault AI") (NASDAQ:DVLT), Data Health Partners, Inc.'s ("DHP") wholly-owned subsidiary REBOOT Health AI, Inc., EOS Technology Holdings, Inc. ("EOS"), Scilex Holding Company ("Scilex") and HealthBridge Adv
- NEWSDataMEDS AI Enters Into Agreement for Commercial Supply of Six Peptides Recommended by FDA Advisory CommitteeCorexa Pharmacy to dispense compounded BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax in accordance with HHS' recently updated Enforcement Discretion PolicyBulk drug substance access facilitates 3PL division's agreements with manufacturers seeking to sell into Corexa Health's 6,500+ Independent Pharmacy Network (IPN) outletHealth Lives Here mobile app to facilitate IPN safety data reporting TAMPA, FL / ACCESS Newswire / November 2, 2026 / DataMeds AI, Inc. ("DataMeds SI," "DataMEDS" or the "Company")(NASDAQ:MEDS), a healthcare company that integrates its health information technology and physical infrastructure with its EinsteinRx™ artificial intelligence platform and PharmacyChain™
- NEWSDataMEDS AI Establishes "Health Lives Here" Community Respiratory Program for Corexa Health Pharmacy NetworkBeing marketed to 6,500+ Corexa Health Pharmacy Network of independent pharmaciesTo be launched first at Corexa Pharmacy in Lakeland, FL retail location in Q4/2026Program will aim to bring best practices for respiratory season to community pharmaciesNuvaxovid COVID vaccine (protein-based / non-mRNA) prioritized for campaign rolloutImprove telehealth availability in the pharmacy through Health Lives Here mobile appTests to include COVID neutralizing antibodies, antibodies & acute respiratory infectionsLong COVID-related biomarkers (cardiovascular, incl microclots; immune; metabolic; etc)Immune profiling for other circulating respiratory diseases (influence, RSV, strep, others)Improve access t
- PRDatavault AI Signs Non-Binding Letter of Intent to Acquire a 19.9% Equity Stake in DataMEDS AI in Consideration of an Expanded Technology LicenseExpanded healthcare platform would bring together patient-controlled data tokenization, biometric medication verification, and automated delivery technologies Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), an Artificial Intelligence Platform ("AIP") company providing data monetization, credentialing, and real-world asset ("RWA") tokenization, today announced that it has entered into a non-binding letter of intent ("LOI") to acquire a 19.9% equity interest in DataMEDS AI, Inc. (NASDAQ:MEDS) ("DataMEDS") in consideration of an expansion of its existing technology license with DataMEDS. The proposed transaction is subject to completion of due diligence and negotiation of
- NEWSDataMEDS AI Enters Into Amended and Restated LOI to License and Acquire IP that Enables Goal-Driven Prescription Drug Telehealth, Medical Drones and Healthcare Blockchain TechnologiesProprietary IP Position Until At Least 2042 to Enable Consolidation of Infrastructure targeting market expected to grow from $9.6 billion in 2025 to $93.4 billion in 2035Customer Acquisition Plan Leverages Existing Relationship with NFL Alumni HealthFinal Guidance issued by FDA Provides Roadmap for Prescription Drug Proprietary Health Lives Here™ App and DelivMeds® SoftwareNetwork of 6,500 Pharmacies to Provide Nationwide Physical Healthcare Outlet TAMPA, FL / ACCESS Newswire / October 22, 2026 / DataMEDS AI, Inc. ("DataMeds SI," "DataMEDS" or the "Company") (NASDAQ:MEDS), a healthcare company that integrates its health information technology and physical infrastructure with its Einste
- NEWSDataMeds Regains Compliance With NASDAQ Listing StandardsTAMPA, FL / ACCESS Newswire / October 20, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its super intelligence (artificial intelligence) platform EinsteinRx™ and smart contracts platform PharmacyChain™, today announced that it has received a notification letter (the "Compliance Notice") from the Listing Qualifications Staff of the Nasdaq Stock Market, LLC ("Nasdaq") dated October 19, 2026, informing DataMEDS that it has regained compliance with Nasdaq Listing Rule 5550(b)(1) (the "Equity Rule"). In order to regain compliance with the Equity Rule, Data
- NEWSDataMeds Applauds FDA's Proposed Interim Access Policy for Compounding Using Certain Peptides and Provides Corexa Health's Peptides RoadmapCorexa Health's three divisions - pharmacy, distribution, and tech & hub - positioned to serve the emerging compounded peptide market TAMPA, FL / ACCESS Newswire / October 16, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its super intelligence platform EinsteinRx™ and smart contracts platform PharmacyChain™, today applauded the issuance of a new policy proposal by the U.S. Food and Drug Administration (FDA) entitled "Interim Access Policy for Compounding Using Certain Peptides." The new proposed policy comes less than three months following the
- NEWSDataMEDS Si Licenses U.S. Rights To Reboot Health AI's Direct-To-Consumer GLP-1 Weight Management PlatformPlatform to be integrated into Health Lives Here app as a subscription offering TAMPA, FL / ACCESS Newswire / October 14, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its super intelligence platform EinsteinRx™ and smart contracts platform PharmacyChain™, today announced that it has entered into an exclusive license, revenue sharing and marketing agreement with REBOOT Health AI, Inc. ("REBOOT") for Direct-to-Consumer (DTC) rights in the United States to REBOOT's proprietary care management platform. The Companies will work together to tailor th
- NEWSDataMEDS SI Provides Business Update On CLIA Lab Helomics And Its Super Intelligence Predictive Oncology DivisionLeading Health IT Company has Implemented Cost Control Measures and Refocused Remaining Workforce Towards ChemoFx® Commercialization with Hospital Systems, HMOs, GPOs and Cancer Centers TAMPA, FL / ACCESS Newswire / October 13, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its super intelligence platform EinsteinRx™ and smart contracts platform PharmacyChain™, today announced that it has implemented cost control measures, primarily through reductions in corporate management positions, to focus the workforce spend on commercializing ChemoFx® as a
- NEWSDataMEDS SI Announces Helomics Receives Medicaid Coverage Policy For Chemofx(R) Assay In Gynecologic CancersHumana adds ChemoFx® to its Medicaid Pharmacogenomics Testing coverage policy TAMPA, FL / ACCESS Newswire / October 12, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company vertically integrating its Health IT and physical infrastructure together with its super intelligence platform EinsteinRx™ and smart contracts platform PharmacyChain™, today announced that its recently acquired CLIA-certified precision oncology laboratory subsidiary Helomics Corporation has received a Medicaid coverage determination in gynecologic cancers for the ChemoFx® Assay, a commercially available chemoresponse test that measures how a patien
- NEWSDatameds AI Files DBAs Datameds SI And Corexa Health SI And Reminds Shareholders Of Record As Of August 7, 2026 Of Dream Bowl Meme Coin I PaymentHealthcare IT Company and its Subsidiary Undertake Action Following US Government's Updated Nomenclature TAMPA, FL / ACCESS Newswire / October 5, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its artificial intelligence platform EinsteinRx™ and smart contracts platform PharmacyChain™, today announced that it has filed DBAs for 'DataMEDS SI' and 'Corexa Health SI'. The Company also reminded shareholders of record as of the close of business on August 7, 2026 (the "Record Date") that the previously announced distribution (the "Distribution") of Dr
- PRThese Stocks Roar into October with Fresh CatalystsDENVER, Oct. 01, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – The markets are charging into October with a wave of fresh milestones and potential catalysts, putting Nexalin Technology (NASDAQ:NXL), Kraig Biocraft Laboratories (OTCQB:KBLB), Veea (NASDAQ:VEEA), and DataMeds AI (NASDAQ:MEDS) firmly in the market spotlight. Nexalin Technology Targets South America with 10-Year Commercial Push Nexalin Technology (NASDAQ:NXL) has turned what was previously a Brazil-focused commercialization effort into a much broader South American expansion story. On October 1, the company announced a definitive exclusive distribution and local-manufacturing agreement with Inovanexa Medical Technologies cov
- NEWSDataMeds AI's Corexa Pharmacy Surpasses $1 Million In Monthly RevenueSeptember 2026 revenue up more than 66 percent from July 2026 with expansion of retail customer base and Tollo Health pharmaceutical-adjunct product launches TAMPA, FL / ACCESS Newswire / October 1, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its artificial intelligence platform EinsteinRx™ and smart contracts platform PharmacyChain™, today provided a revenue update on Corexa Pharmacy, a division of its wholly owned subsidiary Corexa Health.Corexa Pharmacy recorded preliminary, unaudited revenue of more than $1 million for September 2026, an increase of more
- PR4 Explosive Stories Enter the Investor SpotlightDENVER, Sept. 28, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- Kodiak Sciences (NASDAQ:KOD), NeOnc Technologies Holdings (NASDAQ:NTHI), DataMeds AI (NASDAQ:MEDS), and KNOREX (NYSEAMERICAN:KNRX) are each approaching important milestones that could reshape how investors view their pipelines, platforms and near-term prospects. Kodiak Sciences: Five Phase 3 Wins Put Zenkuda on the Regulatory Runway Kodiak Sciences (NASDAQ:KOD) delivered one of the biggest clinical updates in the group. Its pivotal Phase 3 DAYBREAK study produced positive primary-endpoint results for both Zenkuda and tabirafusp-ted in wet age-related macular degeneration. Zenkuda achieved non-inferiority to aflibercept on
- NEWSDataMeds AI and Tollo Health Announce Launch of 'Health Lives Here' Mobile ApplicationHealthcare IT Company and Nutritional Products Maker to Work with NFL Alumni Health to Drive Awareness of GLP-1 Telehealth and Pharmacy Services TAMPA, FL / ACCESS Newswire / September 28, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its artificial intelligence platform EinsteinRx™ and smart contracts platform PharmacyChain™, and Tollo Health, LLC ("Tollo"), a healthcare company commercializing proprietary medical foods and dietary supplements and, through TolloBio, developing biopharmaceutical candidates, today announced the launch of the Health Lives Here m
- NEWSDataMEDS AI To Present At 2026 National Telehealth and Virtual Care SummitInterim Co-CEO to Discuss Growing Patient Desire to Own Health Data TAMPA, FL / ACCESS Newswire / September 25, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its artificial intelligence platform EinsteinRx™ and smart contracts platform PharmacyChain™,announced that its Interim Co-CEO Gerald Commissiong will present "What Patients Really Want" at this year's National Telehealth and Virtual Care Summit in Las Vegas on Monday, September 28, 2026 at 9:15am PT. Mr. Commissiong will discuss the growing desire by patients across the country to own their individual he
- NEWSDataMEDS AI Unveils New Corporate WebsiteUpdated Website Aligns with Pending Marketing Initiatives Following Recent Acquisition of Helomics CLIA-certified Laboratory and Litigation Settlement TAMPA, FL / ACCESS Newswire / September 21, 2026 / DataMEDS AI, Inc. (NASDAQ:MEDS) (the "Company" or "DataMEDS"), a Health IT company vertically integrating health data acquisition and transfer, today announced that it launched its new corporate website www.DataMedsAI.com.This change comes following the recent announcement that DataMEDS has acquired Helomics Corporation's artificial intelligence (AI) Cancer Diagnostics Lab from Axe Compute, and that the Company settled outstanding litigation that resulted in the extinguishment of ~$19 mi
- NEWSDataMeds AI Litigation Settlement Extinguishes ~$19 million In Liabilities and Retires 364,099 Common SharesskedTAMPA, FL / ACCESS Newswire / September 18, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its artificial intelligence platform EinsteinRx™ and smart contracts platform PharmacyChain™,today announced that it has settled litigation related to outstanding debt and receivables related to the May 11, 2023 Wellgistics, LLC Membership Purchase Interest Agreement (the "Settlement Agreement") that were previously carried on the Company's balance sheet as liabilities totaling of approximately $19 million. As part of the Settlement Agreement, the Company retired approximately
- NEWSDataMEDS, AI. Acquires Helomics AI Cancer Diagnostics Lab and Precision Oncology CRO Businesses from Axe ComputeAcquisition Provides Operational Capital to Drive Health Lives Here Campaign and Expand Services into Cancer Management Acquisition Provides Operational Capital to Drive Health Lives Here Campaign and Expand Services into Cancer Management PITTSBURGH, PA / ACCESS Newswire / September 15, 2026 / DataMEDS AI, Inc. (NASDAQ:MEDS) ("DataMEDS"), a Health IT company vertically integrating health data acquisition and transfer, today announced that it completed the acquisition of artificial intelligence cancer diagnostics laboratory business Helomics Corporation ("Helomics") from Axe Compute Inc. (NASDAQ:AGPU) ("Axe Compute" or the "Company"), a neocloud AI infrastructure platform.Under the agr
- PRAxe Compute Sells Helomics AI Cancer Diagnostics Lab Business to DataMEDS AI, Completing Transition to Neocloud GPU-as-a-Service platformPITTSBURGH, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Axe Compute Inc. (NASDAQ:AGPU) ("Axe Compute" or the "Company"), a neocloud AI infrastructure platform, today announced the sale of its legacy artificial intelligence cancer diagnostics laboratory business Helomics Corporation ("Helomics") to DataMEDS AI, Inc. (NASDAQ:MEDS) ("DataMEDS"), a Health IT company vertically integrating health data acquisition and transfer. Under the agreement, Axe Compute sold its wholly-owned subsidiary Helomics in exchange for common shares and common share equivalents of DataMEDS. This agreement provides Axe Compute with potential future returns from DataMEDS common stock while completing its transition to a pur
- NEWSDatameds, AI., and Tollo Health Partner with the NFL Alumni Association for Health Lives Here National Campaign RolloutLeading Healthcare IT Company and Former NFL Players Will Work Together to Provide Rural Communities Access to Telehealth and Pharmacy-based Services Through Health Lives Here Mobile App Leading Healthcare IT Company and Former NFL Players Will Work Together to Provide Rural Communities Access to Telehealth and Pharmacy-based Services Through Health Lives Here Mobile App TAMPA, FL / ACCESS Newswire / September 8, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its artificial intelligence platform EinsteinRx™ and smart contracts platform PharmacyChain™,and Tollo
- NEWSCORRECTION FROM SOURCE: DataMeds AI and Tollo Health Announce Fall 2026 Cold & Flu #Back2School50% Marketing Campaign for Viral Infections Medical Food Galectovid(TM)This version includes the correct image.50% off available online at www.TolloHealth.Shop and www.CorexaRx.comSoon to become available at Health Lives Here™ pharmacies and on Amazon.com TAMPA, FL / ACCESS Newswire / August 27, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS," or the "Company"), an integrated healthcare company leveraging its Health IT infrastructure and artificial intelligence platform EinsteinRx™ combined with blockchain-enabled smart contracts platform PharmacyChain™ to provide integrated solutions for the tokenization of pharmaceutical serialization and the compliant delivery of healthcare and monetization of health data, today announced the U.S. 'direct-
MEDS FAQ
10 questionsWhat does DataMeds AI Inc. do?
DataMEDS AI, Inc. (NASDAQ:MEDS), formerly Wellgistics Health, Inc., is a healthcare company focused on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units through its health information technology platforms to deliver a better experience for consumers and providers. Headquartered in Tampa, Fla., DataMEDS incorporates its EinsteinRx artificial intelligence platform and PharmacyChain blockchain-enabled smart contracts platform into the Health Lives Here mobile application from Tollo Health, LLC, and its pharmacy-related Corexa Health...What is the latest news on MEDS?
In the last 30 days Quantisnow tracked 9 wire items for MEDS: 8 market updates and 1 press release or news item. The most recent was published on November 16, 2026.What is MEDS revenue?
DataMeds AI Inc. (MEDS) reported $7.68M of revenue for the twelve months ended Sep 30, 2026. That is down 77.5% from the year before. Revenue for fiscal 2025 was $23.34M.Is MEDS profitable?
No. DataMeds AI Inc. reported a net loss of $43.37M for the twelve months ended Sep 30, 2026.How much cash and debt does MEDS have?
DataMeds AI Inc. reported $476.6K in cash and cash equivalents and $18.16M of debt on its most recent balance sheet in SEC filings.Where does MEDS stock trade?
DataMeds AI Inc. (MEDS) is listed on NASDAQ.What sector and industry is MEDS in?
DataMeds AI Inc. operates in the Health Care sector, Other Pharmaceuticals industry.What are analysts saying about MEDS?
DataMeds AI Inc. has had 1 recent analyst action on file. The most recent action was from EF Hutton: Buy with a $4.50 price target on 2021-12-09. Recent price targets cluster around $4.50.What companies are similar to MEDS?
Notable peers in the same industry include GH (Guardant Health Inc.), GDRX (GoodRx Holdings Inc.), HIMS (Hims & Hers Health Inc.), PGNY (Progyny Inc.), VCYT (Veracyte Inc.). Compare MEDS side-by-side with any of them on Quantisnow.How can I track MEDS on Quantisnow?
Quantisnow aggregates DataMeds AI Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MEDS to receive live email and push alerts on every new disclosure.